Great resource for drug information, reviews and discussions
Cyclocort (Amcinonide)
How do you rate this drug's effectiveness?
Pharmacology
Information not available
Information not available
Indications
Topical Corticosteroid
Topical Corticosteroid
Contraindications
Fungal diseases of the skin, untreated bacterial infections, tuberculosis of the skin, certain viral diseases such as herpes simplex, vaccinia and varicella. Hypersensitivity to any of the product's components. Not for ophthalmic use.
Fungal diseases of the skin, untreated bacterial infections, tuberculosis of the skin, certain viral diseases such as herpes simplex, vaccinia and varicella. Hypersensitivity to any of the product's components. Not for ophthalmic use.
Safety Information / Warning
Information not available
Information not available
Precautions
Pregnancy and Lactation: The safety of topical corticosteroids during pregnancy or lactation has not been established. Weigh the potential benefit of topical corticosteroids, if used during pregnancy or lactation, against possible hazard to the fetus or the infant being nursed.
Significant systemic absorption may occur when corticosteroids are applied over large areas of the body, especially under occlusive dressings. To minimize this possibility, when long-term therapy is anticipated, interrupt treatment periodically, or treat one area of the body at a time. Avoid contact with the eyes.
Although hypersensitivity reactions have been rare with topically applied corticosteroids, discontinue the cream and initiate appropriate therapy if there are signs of sensitivity.
The use of topical corticosteroids on infected areas should be attended with caution and careful observation, bearing in mind the potential spreading of infection and the possible advisability of discontinuing corticosteroid therapy and/or initiating antibacterial measures. If a symptomatic response is not noted within a few days to a week, discontinue the local application until the infection is brought under control.
Advise patients to inform subsequent physicians of the prior use of corticosteroids.
Occlusive dressings should not be applied if there is an elevation of body temperature.
Prolonged use of topical corticosteroids may produce atrophy of the skin and of s.c. tissues, particularly on flexor surfaces and on the face. If this is noted, discontinue the use of topical corticosteroids.
Topical corticosteroids should be used with caution in patients with stasis dermatitis and other skin diseases associated with impaired circulation.
Pregnancy and Lactation: The safety of topical corticosteroids during pregnancy or lactation has not been established. Weigh the potential benefit of topical corticosteroids, if used during pregnancy or lactation, against possible hazard to the fetus or the infant being nursed.
Significant systemic absorption may occur when corticosteroids are applied over large areas of the body, especially under occlusive dressings. To minimize this possibility, when long-term therapy is anticipated, interrupt treatment periodically, or treat one area of the body at a time. Avoid contact with the eyes.
Although hypersensitivity reactions have been rare with topically applied corticosteroids, discontinue the cream and initiate appropriate therapy if there are signs of sensitivity.
The use of topical corticosteroids on infected areas should be attended with caution and careful observation, bearing in mind the potential spreading of infection and the possible advisability of discontinuing corticosteroid therapy and/or initiating antibacterial measures. If a symptomatic response is not noted within a few days to a week, discontinue the local application until the infection is brought under control.
Advise patients to inform subsequent physicians of the prior use of corticosteroids.
Occlusive dressings should not be applied if there is an elevation of body temperature.
Prolonged use of topical corticosteroids may produce atrophy of the skin and of s.c. tissues, particularly on flexor surfaces and on the face. If this is noted, discontinue the use of topical corticosteroids.
Topical corticosteroids should be used with caution in patients with stasis dermatitis and other skin diseases associated with impaired circulation.
Side Effects / Adverse Effects
When occlusive dressings are used, pustules, miliaria, folliculitis, and pyoderma may occur. The following adverse skin reactions have been reported with the use of topical steroids: dryness, itching, burning, local irritation, striae, skin atrophy, atrophy of s.c. tissues, telangiectasia, hypertrichosis, change in pigmentation, and secondary infection. Adrenal suppression also has been reported following topical corticosteroid therapy. Posterior subcapsular cataracts have been reported following systemic use of corticosteroids.
When occlusive dressings are used, pustules, miliaria, folliculitis, and pyoderma may occur. The following adverse skin reactions have been reported with the use of topical steroids: dryness, itching, burning, local irritation, striae, skin atrophy, atrophy of s.c. tissues, telangiectasia, hypertrichosis, change in pigmentation, and secondary infection. Adrenal suppression also has been reported following topical corticosteroid therapy. Posterior subcapsular cataracts have been reported following systemic use of corticosteroids.
Overdose
Information not available
Information not available
Recommended Dosage
Apply to affected area 2or 3times daily and rub in gently. Application twice a day is usually sufficient.
Apply to affected area 2or 3times daily and rub in gently. Application twice a day is usually sufficient.
Supplied / Packaging
Cream: Each tube contains: amcinonide (a fluorinated corticosteroid) 0.1%, compounded with emulsifying wax, isopropyl palmitate, glycerin, sorbitol solution, lactic acid, purified water and benzyl alcohol 2.0%. Lanolin-, propylene glycol-, tartrazine- and urea-free. Tubes of 15, 30 and 60g.
Ointment: Each tube contains: amcinonide 0.1%, emulsifying wax, benzyl alcohol 2.0%, TENOXII, and white petrolatum. Tartrazine-free. Tubes of 15, 30 and 60g.
Lotion: Each bottle contains: amcinonide 0.1%, emulsifying wax, isopropyl palmitate, glycerin, sorbitol solution, lactic acid, purified water, and benzyl alcohol 1.0%. Lanolin-, propylene glycol-, tartrazine- and urea-free. Bottles of 20 and 60mL.
Cream: Each tube contains: amcinonide (a fluorinated corticosteroid) 0.1%, compounded with emulsifying wax, isopropyl palmitate, glycerin, sorbitol solution, lactic acid, purified water and benzyl alcohol 2.0%. Lanolin-, propylene glycol-, tartrazine- and urea-free. Tubes of 15, 30 and 60g.
Ointment: Each tube contains: amcinonide 0.1%, emulsifying wax, benzyl alcohol 2.0%, TENOXII, and white petrolatum. Tartrazine-free. Tubes of 15, 30 and 60g.
Lotion: Each bottle contains: amcinonide 0.1%, emulsifying wax, isopropyl palmitate, glycerin, sorbitol solution, lactic acid, purified water, and benzyl alcohol 1.0%. Lanolin-, propylene glycol-, tartrazine- and urea-free. Bottles of 20 and 60mL.
